Sophia Genetics, a genomics data analysis company, closed a $110 million Series F financing round.
The round was led by aMoon, a health-tech & life sciences venture fund based in Israel, and Hitachi Ventures, a venture arm of Japanese Hitachi Group.
Existing investors Swisscom Ventures, Endeavour Vision, Generation Investment Management, Alychlo, Eurazeo Growth, and new investors ACE & Company and Famille C Invest, also participated.
According to the company, the new funding round will help expand its business in the US and Asian markets, develop the data analysis platform multimodal capabilities, accelerate adoption worldwide. The platform is used by over 1,000 healthcare institutions and has analyzed 600,000 genomic profiles, up to 17,000 new profiles a month, the company said.
“The overall demand for Data-Driven Medicine is rapidly growing, and the next step is to successfully combine multiple sources of data to better address clinicians’ needs,” said Dr. Tomer Berkovitz, Partner & CFO of aMoon. “With this shift, more complex data will be generated, and we believe that Sophia’s decentralized model will play a pivotal role in empowering health organizations to offer better patient care.”
Sophia Genetics, founded in 2011, raised over $250 million to date. The company employs more than 300 people with an office in Switzerland and the United States.
“Since inception, we knew that leveraging a wide range of data modalities powered by cutting-edge technologies was key to sustainably deliver better outcomes to the global healthcare community,” concluded Jurgi Camblong, CEO and Founder at Sophia Genetics. “Now, with this new funding round, we can embark on the next stage of our development and take our collaborative approach further, delivering intelligent medicine, together.”
Genomics analytics companies raised $2 billion since 2011, according to Mercom Database. Recently, DNAnexus, cloud-based genome informatics and data management software platform, closed a $100 million in Series G funding round.
